Top

Published in:

01-02-2022

Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population

Authors: Saeed Elahirad, Daniel Elieh Ali Komi, Amir Kiani, Ehsan Mohammadi-Noori, Asad Vaisi‑Raygani, Hadi Mozafari, Fariborz Bahrehmand, Mohammadreza Saidi, Vahid Toupchi-Khosroshahi, Nahid Salehi

Published in: Cardiovascular Toxicology | Issue 2/2022

Abstract

The serum levels and activity of matrix metalloproteinases (MMPs) are associated with the risk of coronary artery calcification (CAC). We sought to investigate the association between MMP-2 -1575G>A (rs243866) and MMP-9 -1562 C>T (rs3918242) SNPs with MMP-2 and MMP-9 serum levels and activity in individuals with CAC. One hundred and fifty-five cases with CAC and 155 healthy individuals as control group from West of Iran were included and frequency of genotypes and alleles of rs243866 and rs3918242 in MMP-2 and MMP-9 genes were determined using PCR–RFLP. We also investigated the serum levels of MMP-2 and MMP-9 and their activity using ELISA and gelatin zymography, respectively. Additionally, serum biochemical parameters including FBS (fasting blood sugar), urea, creatinine, cholesterol, triglyceride, HDL (high-density lipoprotein), LDL (low-density lipoprotein), calcium, and phosphorus as well as blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) were measured. Our results showed that both serum levels of MMP-2 and MMP-9 (P < 0.001) and their activity (P < 0.001) were higher in individuals with CAC when compared to the control group. Carrying A and T alleles in MMP-2 -1575G>A (rs243866) and MMP-9 -1562 C>T (rs3918242) SNPs, respectively, may predispose the individuals to CAC by acting as the risk factors. Serum levels and activity of MMP-2 and MMP-9 were found to be higher in CAC cases when compared to the healthy controls. Carriers of A allele in rs243866 SNP and T allele in rs3918242 SNP were shown to have higher MMP-2 and MMP-9 serum levels and activity that may result in increased ECM degradation and support the initiation and development of calcification.

Liu, W., Zhang, Y., Yu, C. M., Ji, Q. W., Cai, M., Zhao, Y. X., & Zhou, Y. J. (2015). Current understanding of coronary artery calcification. Journal of Geriatric Cardiology: JGC, 12, 668–675.PubMedPubMedCentral

Mohammadi-Noori, E., Salehi, N., Mozafari, H., EliehAliKomi, D., Saidi, M., Bahrehmand, F., Vaisi-Raygani, A., Elahirad, S., Moini, A., & Kiani, A. (2020). Association of AHSG gene polymorphisms with serum Fetuin-A levels in individuals with cardiovascular calcification in west of Iran. Molecular Biology Reports, 47, 1809–1820.PubMedCrossRef

Hillerson, D., Wool, T., Ogunbayo, G. O., Sorrell, V. L., & Leung, S. W. (2020). Incidental coronary artery calcification and stroke risk in patients with atrial fibrillation. AJR: American Journal of Roentgenology, 215, 1–7.CrossRef

Wang, L., Jerosch-Herold, M., Jacobs, D. R., Jr., Shahar, E., Detrano, R., & Folsom, A. R. (2006). Coronary artery calcification and myocardial perfusion in asymptomatic adults: The MESA (Multi-Ethnic Study of Atherosclerosis). Journal of the American College of Cardiology, 48, 1018–1026.PubMedPubMedCentralCrossRef

Mori, H., Torii, S., Kutyna, M., Sakamoto, A., Finn, A. V., & Virmani, R. (2018). Coronary artery calcification and its progression: what does it really mean? CJACC Cardiovascular Imaging, 11, 127–142.PubMedCrossRef

Joseph, T. P., Kotecha, N. S., Kumar, H. B. C., Jain, N., Kapoor, A., Kumar, S., Bhatia, E., Mishra, P., & Sahoo, S. K. (2020). Coronary artery calcification, carotid intima-media thickness and cardiac dysfunction in young adults with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 34, 107609.PubMedCrossRef

Motro, M., & Shemesh, J. (2001). Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension (Dallas, Tex.: 1979), 37, 1410–1413.CrossRef

Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., Pettinger, M. B., Gass, M., Margolis, K. L., Nathan, L., Ockene, J. K., Prentice, R. L., Robbins, J., & Stefanick, M. L. (2007). Estrogen therapy and coronary-artery calcification. The New England Journal of Medicine, 356, 2591–2602.PubMedCrossRef

Kalil, R. S., Flanigan, M., Stanford, W., & Haynes, W. G. (2012). Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: A prospective pilot study. Clinical Nephrology, 78, 1–9.PubMedCrossRef

10.

Chertow, G. M., Burke, S. K., & Raggi, P. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney international, 62, 245–252.PubMedCrossRef

11.

Chen, C. L., Chen, N. C., Wu, F. Z., & Wu, M. T. (2020). Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporosis International, 31, 1507–1516.PubMedCrossRef

12.

Elieh Ali Komi, D., & Grauwet, K. (2018). Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clinical Reviews in Allergy & Immunology, 54, 432–445.CrossRef

13.

EliehAliKomi, D., Shafaghat, F., & Haidl, G. (2020). Significance of mast cells in spermatogenesis, implantation, pregnancy, and abortion: Cross talk and molecular mechanisms. American Journal of Reproductive Immunology (New York, N.Y.: 1989), 83, e13228.

14.

Komi, D. E. A., & Redegeld, F. A. (2020). Role of mast cells in shaping the tumor microenvironment. Clinical Reviews in Allergy & Immunology, 58, 313–325.CrossRef

15.

Komi, D. E. A., Khomtchouk, K., & Santa Maria, P. L. (2020). A review of the contribution of mast cells in wound healing: Involved molecular and cellular mechanisms. Clinical Reviews in Allergy & Immunology, 58, 298–312.CrossRef

16.

Rao, V. H., Lees, G. E., Kashtan, C. E., Nemori, R., Singh, R. K., Meehan, D. T., Rodgers, K., Berridge, B. R., Bhattacharya, G., & Cosgrove, D. (2003). Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS). Kidney International, 63, 1736–1748.PubMedCrossRef

17.

Najafi, K., Komi, D. E. A., Khazaie, H., Moini, A., Vaisi, A., Raygani, Ahmadi, H. R., Ghadami, M. R., & Kiani, A. (2019). Investigation of serum levels and activity of matrix metalloproteinases 2 and 9 (MMP2, 9) in opioid and methamphetamine-dependent patients. Acta Medica Iranica, 56, 559–562.

18.

Mirabdaly, S., Elieh Ali Komi, D., Shakiba, Y., Moini, A., & Kiani, A. (2020). Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties. Molecular Biology Reports, 47, 1187–1197.PubMedCrossRef

19.

Chen, N. X., O’Neill, K. D., Chen, X., Kiattisunthorn, K., Gattone, V. H., & Moe, S. M. (2011). Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. American Journal of Nephrology, 34, 211–219.PubMedPubMedCentralCrossRef

20.

Radunovic, M., Nikolic, N., Milenkovic, S., Tomanovic, N., Boricic, I., Dimitrijevic, M., Novakovic, I., & Basta-Jovanovic, G. (2016). The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. Journal of BUON, 21, 597–602.PubMed

21.

Singh, K., Agrawal, N. K., Gupta, S. K., & Singh, K. (2013). A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. The International Journal of Lower Extremity Wounds, 12, 199–204.PubMedCrossRef

22.

Habel, A. F., Ghali, R. M., Bouaziz, H., Daldoul, A., Hadj-Ahmed, M., Mokrani, A., Zaied, S., Hechiche, M., Rahal, K., Yacoubi-Loueslati, B., & Almawi, W. Y. (2019). Common matrix metalloproteinase-2 gene variants and altered susceptibility to breast cancer and associated features in Tunisian women. Tumour Biology, 41, 1010428319845749.PubMedCrossRef

23.

Ting, W. C., Chen, L. M., Pao, J. B., Yang, Y. P., You, B. J., Chang, T. Y., Lan, Y. H., Lee, H. Z., & Bao, B. Y. (2013). Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. International Journal of Medical Sciences, 10, 1022–1027.PubMedPubMedCentralCrossRef

24.

Tian, Y., An, F., Wang, J., Liu, C., Wu, H., Cao, Y., Wang, J., & Wang, G. (2019). MMP2 and MMP10 polymorphisms are related to steroid-induced osteonecrosis of the femoral head among Chinese Han population. BioMed Research International, 2019, 8298193.PubMedPubMedCentralCrossRef

25.

Chacon-Cortes, D., & Griffiths, L. (2014). Methods for extracting genomic DNA from whole blood samples: Current perspectives. Journal of Biorepository Science for Applied Medicine, 2, 1–9.

26.

EliehAliKomi, D., Sadeghi-Shabestari, M., Shanebandi, D., Babaloo, Z., Razavi, A., Sadigh-Eteghad, S., & Kazemi, T. (2019). Investigation of chitinase3like-1 (Chiti3L1) gene polymorphism (rs4950928) with susceptibility to allergic asthma in Iranian Northwestern Azeri population. Research in Molecular Medicine, 7, 17–24.CrossRef

27.

Aslanian-Kalkhoran, L., Elieh-Ali-Komi, D., Sadeghi-Shabestari, M., Shanebandi, D., Babaloo, Z., Razavi, A., Sadigh-Eteghad, S., & Kazemi, T. (2017). Investigation of Fc receptor-like 3 (FCRL-3) gene polymorphism (rs7528684) with susceptibility to allergic asthma in Iranian North-Western Azeri population. Clinical Laboratory, 63, 1301–1305.PubMedCrossRef

28.

Rybakowski, J. K. (2009). Matrix metalloproteinase-9 (MMP9)—A mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovascular Psychiatry and Neurology, 2009, 904836.PubMedPubMedCentralCrossRef

29.

Fanjul-Fernández, M., Folgueras, A. R., Cabrera, S., & López-Otín, C. (2010). Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta, 1803, 3–19.PubMedCrossRef

30.

Bahrehmand, F., Vaisi-Raygani, A., Kiani, A., Rahimi, Z., Tavilani, H., Ardalan, M., Vaisi-Raygani, H., Shakiba, E., & Pourmotabbed, T. (2015). Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: Correlation with systemic inflammatory markers and oxidative stress. Lupus, 24, 597–605.PubMedCrossRef

31.

Lehmann, D. J., Williams, J., McBroom, J., & Smith, A. D. (2001). Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups. Neuroscience, 108, 541–554.PubMedCrossRef

32.

Raygani, A. V., Zahrai, M., Soltanzadeh, A., Doosti, M., Javadi, E., & Pourmotabbed, T. (2004). Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s disease. Neuroscience Letters, 371, 142–146.PubMedCrossRef

33.

Shahmohamadnejad, S., Vaisi-Raygani, A., Shakiba, Y., Kiani, A., Rahimi, Z., Bahrehmand, F., Shakiba, E., & Pourmotabbed, T. (2015). Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: Correlation with systemic inflammatory markers and oxidative stress, preliminary report. Clinical Biochemistry, 48, 63–69.PubMedCrossRef

34.

Wågsäter, D., Zhu, C., Björkegren, J., Skogsberg, J., & Eriksson, P. (2011). MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(−/−)Apob(100/100) mouse. International Journal of Molecular Medicine, 28, 247–253.PubMed

35.

Soliman, A. R., Sadek, K. M., Thabet, K. K., Ahmed, D. H., & Mohamed, O. M. (2019). The role of matrix metalloproteinases 2 in atherosclerosis of patients with chronic kidney disease in type 2 diabetes. Saudi Journal of Kidney Diseases and Transplantation, 30, 387–393.PubMedCrossRef

36.

Qin, X., Corriere, M. A., Matrisian, L. M., & Guzman, R. J. (2006). Matrix metalloproteinase inhibition attenuates aortic calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1510–1516.PubMedCrossRef

37.

Liu, R., Chen, B., Chen, J., & Lan, J. (2018). Leptin upregulates smooth muscle cell expression of MMP-9 to promote plaque destabilization by activating AP-1 via the leptin receptor/MAPK/ERK signaling pathways. Experimental and Therapeutic Medicine, 16, 5327–5333.PubMedPubMedCentral

38.

Kieffer, P., Giummelly, P., Schjoth, B., Carteaux, J. P., Villemot, J. P., Hornebeck, W., & Atkinson, J. (2001). Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis, 157, 251–254.PubMedCrossRef

39.

Harendza, S., Lovett, D. H., Panzer, U., Lukacs, Z., Kuhnl, P., & Stahl, R. A. (2003). Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. The Journal of Biological Chemistry, 278, 20490–20499.PubMedCrossRef

40.

Dofara, S. G., Chang, S. L., & Diorio, C. (2020). Gene polymorphisms and circulating levels of MMP-2 and MMP-9: A review of their role in breast cancer risk. Anticancer Research, 40, 3619–3631.PubMedCrossRef

41.

Zhen, G. D., Zhao, L. B., Wu, S. S., Chen, M. Y., Li, Z. H., Zhou, S. Z., & Li, Z. F. (2017). Associations of MMP-2 and MMP-9 gene polymorphism with ulinastatin efficacy in patients with severe acute pancreatitis. Bioscience Reports, 37, 4.CrossRef

42.

Rollin, J., Régina, S., Vourc’h, P., Iochmann, S., Bléchet, C., Reverdiau, P., & Gruel, Y. (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 56, 273–280.CrossRef

43.

Hua, Y., Song, L., Wu, N., Lu, X., Meng, X., Gu, D., & Yang, Y. (2009). Polymorphisms of MMP-2 gene are associated with systolic heart failure risk in Han Chinese. The American Journal of the Medical Sciences, 337, 344–348.PubMedCrossRef

44.

Beber, A. R., Polina, E. R., Biolo, A., Santos, B. L., Gomes, D. C., La Porta, V. L., Olsen, V., Clausell, N., Rohde, L. E., & Santos, K. G. (2016). Matrix metalloproteinase-2 polymorphisms in chronic heart failure: Relationship with susceptibility and long-term survival. PLoS ONE, 11, e0161666.PubMedPubMedCentralCrossRef

45.

Pérez-Hernández, N., Vargas-Alarcón, G., Martínez-Rodríguez, N., Martínez-Ríos, M. A., Peña-Duque, M. A., Peña-Díaz Ade, L., Valente-Acosta, B., Posadas-Romero, C., Medina, A., & Rodríguez-Pérez, J. M. (2012). The matrix metalloproteinase 2–1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients. Journal of Atherosclerosis and Thrombosis, 19, 718–727.PubMedCrossRef

46.

Wu, H. D., Bai, X., Chen, D. M., Cao, H. Y., & Qin, L. (2013). Association of genetic polymorphisms in matrix metalloproteinase-9 and coronary artery disease in the Chinese Han population: A case–control study. Genetic Testing and Molecular Biomarkers, 17, 707–712.PubMedPubMedCentralCrossRef

47.

Saedi, M., Vaisi-Raygani, A., Khaghani, S., Shariftabrizi, A., Rezaie, M., Pasalar, P., Rahimi, Z., & Pourmotabbed, T. (2012). Matrix metalloproteinase-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease. Molecular Biology Reports, 39, 555–562.PubMedCrossRef

48.

Bahrehmand, F., Vaisi-Raygani, A., Kiani, A., Rahimi, Z., Tavilani, H., Navabi, S. J., Shakiba, E., Hassanzadeh, N., & Pourmotabbed, T. (2012). Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus, 21, 616–624.PubMedCrossRef

49.

Reynolds, J. J. (1996). Collagenases and tissue inhibitors of metalloproteinases: A functional balance in tissue degradation. Oral Diseases, 2, 70–76.PubMedCrossRef

50.

Elieh Ali Komi, D., & Bjermer, L. (2019). Mast cell-mediated orchestration of the immune responses in human allergic asthma: Current insights. Clinical Reviews in Allergy & Immunology, 56, 234–247.CrossRef

Title: Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population
Authors: Saeed Elahirad
Daniel Elieh Ali Komi
Amir Kiani
Ehsan Mohammadi-Noori
Asad Vaisi‑Raygani
Hadi Mozafari
Fariborz Bahrehmand
Mohammadreza Saidi
Vahid Toupchi-Khosroshahi
Nahid Salehi
Publication date: 01-02-2022
Publisher: Springer US
Published in: Cardiovascular Toxicology / Issue 2/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-021-09707-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy

In Vivo Cardiotoxic Potential of Micrurus frontalis Venom

Maternal Nanomaterial Inhalation Exposure: Critical Gestational Period in the Uterine Microcirculation is Angiotensin II Dependent

Yohimbine Directly Induces Cardiotoxicity on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Curcumin Ameliorates Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity Via Suppressing Oxidative Stress and Modulating iNOS, NF-κB, and TNF-α in Rats

MiR-7a-5p Attenuates Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis by Targeting VDAC1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page